Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""ANAPLASTIC lymphoma kinase"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 7570
Tytuł:
Clinical outcomes of ALK + non-small cell lung cancer in Denmark.
Autorzy:
Hansen KH; Department of Oncology, Odense University Hospital, Odense, Denmark.
Johansen JS; Department of Oncology, Herlev and Gentofte University Hospital, Copenhagen, Denmark.
Urbanska EM; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Meldgaard P; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
Hjorth-Hansen P; Department of Oncology, Aalborg University Hospital, Aalborg, Denmark.
Kristiansen C; Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark.
Stelmach M; Department of Oncology, Næstved Hospital, Næstved, Denmark.
Santoni-Rugiu E; Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Ulhøi MP; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
Dydensborg AB; Takeda Pharma A/S, Copenhagen, Denmark.
Dünweber C; Takeda Pharma A/S, Copenhagen, Denmark.
Andersen JL; Department of Oncology, Herlev and Gentofte University Hospital, Copenhagen, Denmark.
Pokaż więcej
Źródło:
Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2023 Dec; Vol. 62 (12), pp. 1775-1783. Date of Electronic Publication: 2023 Nov 25.
Typ publikacji:
Journal Article
MeSH Terms:
Anaplastic Lymphoma Kinase*/antagonists & inhibitors
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/mortality
Lung Neoplasms*/drug therapy
Lung Neoplasms*/epidemiology
Lung Neoplasms*/metabolism
Protein Kinase Inhibitors*/therapeutic use
Female ; Humans ; Middle Aged ; Crizotinib/therapeutic use ; Denmark/epidemiology ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Anaplastic lymphoma kinase overexpression enhances aggressive phenotypic characteristics of endometrial carcinoma.
Autorzy:
Yokoi A; Department of Pathology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-Ku, Sagamihara, Kanagawa, 252-0374, Japan.
Nakamura Y; Department of Pathology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-Ku, Sagamihara, Kanagawa, 252-0374, Japan.
Hashimura M; Department of Pathology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-Ku, Sagamihara, Kanagawa, 252-0374, Japan.
Oguri Y; Department of Pathology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-Ku, Sagamihara, Kanagawa, 252-0374, Japan.
Matsumoto T; Department of Pathology, Kitasato University School of Allied Health Science, 1-15-1 Kitasato, Minami-Ku, Sagamihara, Kanagawa, 252-0374, Japan.
Nakagawa M; Department of Pathology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-Ku, Sagamihara, Kanagawa, 252-0374, Japan.
Ishibashi Y; Department of Pathology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-Ku, Sagamihara, Kanagawa, 252-0374, Japan.
Ito T; Department of Pathology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-Ku, Sagamihara, Kanagawa, 252-0374, Japan.
Ohhigata K; Department of Pathology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-Ku, Sagamihara, Kanagawa, 252-0374, Japan.
Harada Y; Department of Pathology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-Ku, Sagamihara, Kanagawa, 252-0374, Japan.
Fukagawa N; Department of Pathology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-Ku, Sagamihara, Kanagawa, 252-0374, Japan.
Saegusa M; Department of Pathology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-Ku, Sagamihara, Kanagawa, 252-0374, Japan. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2023 Aug 17; Vol. 23 (1), pp. 765. Date of Electronic Publication: 2023 Aug 17.
Typ publikacji:
Journal Article
MeSH Terms:
Anaplastic Lymphoma Kinase*/genetics
Endometrial Neoplasms*/genetics
Female ; Humans ; Cytoplasm ; Phenotype ; RNA, Messenger
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
LTK mutations responsible for resistance to lorlatinib in non-small cell lung cancer harboring CLIP1-LTK fusion.
Autorzy:
Mori S; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, 277-8577, Japan.
Izumi H; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, 277-8577, Japan.
Araki M; Graduate School of Medicine, Kyoto University, Shogoin-Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan.
Liu J; Division of Translational Genomics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, 277-8577, Japan.
Tanaka Y; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, 277-8577, Japan.
Kagawa Y; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, 277-8577, Japan.
Sagae Y; Graduate School of Medicine, Kyoto University, Shogoin-Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan.
Ma B; RIKEN Center for Computational Science, Kobe, Hyogo, 650-0047, Japan.
Isaka Y; RIKEN Center for Computational Science, Kobe, Hyogo, 650-0047, Japan.
Sasakura Y; RIKEN Center for Computational Science, Kobe, Hyogo, 650-0047, Japan.
Kumagai S; Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, 277-8577, Japan.
Sakae Y; Division of Translational Genomics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, 277-8577, Japan.
Tanaka K; Division of Translational Genomics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, 277-8577, Japan.
Shibata Y; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, 277-8577, Japan.
Udagawa H; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, 277-8577, Japan.
Matsumoto S; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, 277-8577, Japan.
Yoh K; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, 277-8577, Japan.
Okuno Y; Graduate School of Medicine, Kyoto University, Shogoin-Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan.
Goto K; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, 277-8577, Japan.
Kobayashi SS; Division of Translational Genomics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, 277-8577, Japan. .; Department of Integrated Biosciences, Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, 277-8561, Japan. .; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA. .
Pokaż więcej
Źródło:
Communications biology [Commun Biol] 2024 Apr 04; Vol. 7 (1), pp. 412. Date of Electronic Publication: 2024 Apr 04.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Aminopyridines*
Lactams*
Pyrazoles*
Humans ; Anaplastic Lymphoma Kinase/genetics ; Anaplastic Lymphoma Kinase/therapeutic use ; Drug Resistance, Neoplasm/genetics ; Lactams, Macrocyclic/pharmacology ; Lactams, Macrocyclic/therapeutic use ; Mutation ; Cytoskeletal Proteins/genetics ; Receptor Protein-Tyrosine Kinases/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Real-world outcome of crizotinib for anaplastic lymphoma kinase-positive lung cancer: Multicenter retrospective analysis in South Korea.
Autorzy:
Jeon DS; Department of Pulmonary and Critical Care Medicine, Nowon Eulji Medical Center, University of Eulji, Seoul, South Korea.
Park CK; Department of Pulmonary and Critical Care Medicine, Chonnam National University Hwasun hospital, Chonnam National University, Jeollanam-do, Republic of Korea.
Kim SJ; Department of Internal Medicine, Postech-Catholic Biomedical Engineering Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Park CK; Department of Pulmonary and Critical Care Medicine, Catholic University of Korean Yeouido Saint Mary's Hospital, Seoul, Korea.
Chang YS; Department of Internal Medicine, Yonsei University College of Medicine, 8th Floor Annex Building, Yongdong Severance Hospital, Seoul, Republic of Korea.
Jung CY; Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, Korea.
Lee SY; Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea.
Lee SY; Division of Pulmonary and Critical Care Medicine, Kyungpook National University Chilgok Hospital, Daegu, Korea.
Ryu JS; Department of Pulmonary and Critical Care Medicine, Inha University Hospital, Incheon, Republic of Korea.
Lee JE; Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea.
Lee KY; Department of Pulmonary Medicine, Konkuk University School of Medicine, Seoul, Republic of Korea.
Jang TW; Department of Internal Medicine, Kosin University Medical College, Pusan, Korea.
Jang SH; Department of Pulmonary, Allergy and Critical Care Medicine, Hallym University Sacred Heart Hospital, Anyang, Republic of Korea.
Yoon SH; Department of Internal Medicine, School of Medicine, Pusan National University, Yangsan, Republic of Korea.
Lee SH; Division of Pulmonology, Institute of Chest Disease, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Choi CM; Department of Pulmonary and Critical Care Medicine, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, Republic of Korea.; Department of Oncology, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Kim HR; Department of Pulmonary and Critical Care Medicine, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Kim YJ; Department of Pulmonary and Critical Care Medicine, Nowon Eulji Medical Center, University of Eulji, Seoul, South Korea.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2024 Feb; Vol. 15 (6), pp. 448-457. Date of Electronic Publication: 2024 Jan 03.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Lung Neoplasms*/pathology
Carcinoma, Non-Small-Cell Lung*/pathology
Humans ; Male ; Middle Aged ; Female ; Crizotinib/therapeutic use ; Anaplastic Lymphoma Kinase/therapeutic use ; Receptor Protein-Tyrosine Kinases/therapeutic use ; Protein Kinase Inhibitors
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis.
Autorzy:
Zhao M; Department of Pharmacoeconomics, School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, China.; Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, Jiangsu, China.
Shao T; Department of Pharmacoeconomics, School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, China.; Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, Jiangsu, China.
Shao H; Department of Pharmacoeconomics, School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, China.; Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, Jiangsu, China.
Zhou C; Shanghai Pulmonary Hospital, Tongji University, Shanghai, China. .
Tang W; Department of Pharmacoeconomics, School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, China. .; Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, Jiangsu, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2024 Feb 08; Vol. 24 (1), pp. 186. Date of Electronic Publication: 2024 Feb 08.
Typ publikacji:
Meta-Analysis; Systematic Review; Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Lung Neoplasms*/drug therapy
Lung Neoplasms*/chemically induced
Sulfones*
Aminopyridines*
Lactams*
Pyrimidines*
Pyrazoles*
Organophosphorus Compounds*
Humans ; Crizotinib/therapeutic use ; Network Meta-Analysis ; Bayes Theorem ; Quality of Life ; Anaplastic Lymphoma Kinase ; Protein Kinase Inhibitors/therapeutic use ; Carbazoles/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Mitoxantrone and abacavir: An ALK protein-targeted in silico proposal for the treatment of non-small cell lung cancer.
Autorzy:
Faya Castillo JE; Departamento de Ciencias Básicas, Bioética y la Vida Humana, Facultad de Medicina Humana, Universidad de Piura, Lima, Perú.
Zapata Dongo RJ; Departamento de Ciencias Básicas, Bioética y la Vida Humana, Facultad de Medicina Humana, Universidad de Piura, Lima, Perú.
Wong Chero PA; Departamento de Ciencias de la Medicina, Facultad de Medicina Humana, Universidad de Piura, Lima, Perú.
Infante Varillas SF; Departamento de Ciencias Básicas, Bioética y la Vida Humana, Facultad de Medicina Humana, Universidad de Piura, Lima, Perú.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2024 Feb 06; Vol. 19 (2), pp. e0295966. Date of Electronic Publication: 2024 Feb 06 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Lung Neoplasms*/genetics
Cyclopropanes*
Dideoxyadenosine/*analogs & derivatives
Humans ; Mitoxantrone/therapeutic use ; Molecular Docking Simulation ; Anaplastic Lymphoma Kinase/genetics ; Receptor Protein-Tyrosine Kinases/metabolism ; Protein Kinase Inhibitors/pharmacology ; Oncogene Proteins, Fusion/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The association of genomic alterations with PD-L1 expression in Chinese patients with EGFR/ALK wild-type lung adenocarcinoma and potential predictive value of Hippo pathway mutations to immunotherapy.
Autorzy:
Liu F; Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zhang X; Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Lu M; Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Liu C; Genecast Biotechnology Co., Ltd, Wuxi, Jiangsu, China.
Zhang X; Genecast Biotechnology Co., Ltd, Wuxi, Jiangsu, China.
Chu Q; Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Chen Y; Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zhang P; Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2024 Feb; Vol. 13 (3), pp. e7038.
Typ publikacji:
Journal Article
MeSH Terms:
Adenocarcinoma of Lung*/genetics
Adenocarcinoma of Lung*/therapy
Lung Neoplasms*/therapy
Lung Neoplasms*/drug therapy
Humans ; Anaplastic Lymphoma Kinase/genetics ; B7-H1 Antigen/genetics ; B7-H1 Antigen/metabolism ; CD8-Positive T-Lymphocytes/metabolism ; China ; ErbB Receptors/genetics ; ErbB Receptors/metabolism ; Genomics ; Hippo Signaling Pathway/genetics ; Immunotherapy ; Mutation ; Retrospective Studies ; Tumor Microenvironment/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A case of inflammatory myofibroblastic tumor harboring EML4-ALK fusion with a brain metastasis responding to alectinib.
Autorzy:
Sakoda S; Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.; Department of Respiratory Medicine, Kitakyushu Municipal Medical Center, Fukuoka, Japan.
Tanaka K; Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Koga Y; Department of Respiratory Medicine, Kitakyushu Municipal Medical Center, Fukuoka, Japan.
Mikumo H; Department of Respiratory Medicine, Kitakyushu Municipal Medical Center, Fukuoka, Japan.
Tsuchiya-Kawano Y; Department of Respiratory Medicine, Kitakyushu Municipal Medical Center, Fukuoka, Japan.
Harada E; Department of Respiratory Medicine, Kitakyushu Municipal Medical Center, Fukuoka, Japan.
Tamiya S; Department of Pathology, Kitakyushu Municipal Medical Center, Fukuoka, Japan.
Okamoto I; Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2024 Feb; Vol. 15 (5), pp. 415-418. Date of Electronic Publication: 2024 Jan 11.
Typ publikacji:
Case Reports
MeSH Terms:
Brain Neoplasms*/drug therapy
Brain Neoplasms*/genetics
Brain Neoplasms*/secondary
Granuloma, Plasma Cell*/pathology
Female ; Humans ; Aged ; Anaplastic Lymphoma Kinase/genetics ; Piperidines/therapeutic use ; Carbazoles/therapeutic use ; Oncogene Proteins, Fusion/genetics
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
High efficacy of brigatinib for brain metastases in ALK fusion gene-positive non-small cell lung cancer: A case series.
Autorzy:
Morikawa K; Division of Respiratory Diseases, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.
Numata Y; Division of Respiratory Diseases, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.
Shinozaki Y; Division of Respiratory Diseases, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.
Kaneko S; Division of Respiratory Diseases, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.
Matsushima A; Division of Respiratory Diseases, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.
Nishida M; Division of Respiratory Diseases, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.
Kida H; Division of Respiratory Diseases, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.
Handa H; Division of Respiratory Diseases, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.
Nishine H; Division of Respiratory Diseases, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.
Mineshita M; Division of Respiratory Diseases, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2024 Feb; Vol. 15 (6), pp. 496-499. Date of Electronic Publication: 2023 Dec 30.
Typ publikacji:
Case Reports
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/pathology
Brain Neoplasms*/drug therapy
Brain Neoplasms*/genetics
Brain Neoplasms*/secondary
Organophosphorus Compounds*
Pyrimidines*
Female ; Humans ; Anaplastic Lymphoma Kinase ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Neoadjuvant Lorlatinib Induces Pathological Complete Response in Advanced ALK-Positive Lung Cancer: A Case Report.
Autorzy:
Li J; Department of Immunology, University of South Florida, Tampa, FL, USA.
Liu J; Department of Thoracic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China (mainland).
Zhang G; Department of Respiratory and Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China (mainland).
Hu W; Department of Thoracic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China (mainland).
Wang X; Department of Thoracic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China (mainland).
Liu J; Department of Thoracic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China (mainland).
Pokaż więcej
Źródło:
The American journal of case reports [Am J Case Rep] 2023 Nov 07; Vol. 24, pp. e942150. Date of Electronic Publication: 2023 Nov 07.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Lung Neoplasms*/drug therapy
Lung Neoplasms*/pathology
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/pathology
Male ; Humans ; Middle Aged ; Neoadjuvant Therapy ; Anaplastic Lymphoma Kinase/genetics ; Anaplastic Lymphoma Kinase/therapeutic use ; Lactams, Macrocyclic/therapeutic use ; Protein Kinase Inhibitors/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Real world study of safety and efficacy of lorlatinib as second line and beyond in ALK-rearranged advanced non-small cell lung cancer patients in India - a multicentre chart review study (ROSELAND).
Autorzy:
Biswas, Bivas
Ghadyalpatil, Nikhil S.
Patil, Shekar
Patel, Amol
Ganguly, Sandip
Rathore, Anvesh
Guleria, Bhupesh
Tarannum, Cpalli Firdouse
Ghosh, Joydeep
Kondapally, Mary Sravani
Thippeswamy, Ravi
Reddy, Shashidhara Haragadde Poppa
Roy, Somnath
Pokaż więcej
Źródło:
Ecancermedicalscience. 2024, Vol. 18 Issue 1651-1674, p1-10. 10p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel Discussion.
Autorzy:
Gridelli, Cesare (AUTHOR)
Tiseo, Marcello (AUTHOR)
Cortinovis, Diego Luigi (AUTHOR)
Migliorino, Maria Rita (AUTHOR)
Barbieri, Vito (AUTHOR)
Bironzo, Paolo (AUTHOR)
Bearz, Alessandra (AUTHOR)
Attili, Ilaria (AUTHOR)
de Marinis, Filippo (AUTHOR)
Pokaż więcej
Źródło:
Current Oncology. Nov2023, Vol. 30 Issue 11, p10033-10042. 10p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Gastric and cardiac inflammatory myofibroblastic tumor: an extremely rare case.
Autorzy:
Huang Y; Department of Ultrasound Medicine, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, People's Republic of China.
Zhang M; Department of General Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, People's Republic of China.
Li Q; Department of Image, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, People's Republic of China.
Huang Q; Department of General Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, People's Republic of China. .
Pokaż więcej
Źródło:
Journal of cardiothoracic surgery [J Cardiothorac Surg] 2024 Jan 29; Vol. 19 (1), pp. 31. Date of Electronic Publication: 2024 Jan 29.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Laparoscopy*
Heart Neoplasms*/diagnosis
Heart Neoplasms*/surgery
Male ; Humans ; Middle Aged ; Anaplastic Lymphoma Kinase ; Stomach
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Discovery of novel 2-aminopyridine derivatives as ROS1 and ALK dual inhibitors to combat drug-resistant mutants including ROS1 .
Autorzy:
Liu S; Affiliated Foshan Maternity & Child Healthcare Hospital, Southern Medicinal University (Foshan Maternity & Child Healthcare Hospital), Foshan, China.; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
Huang C; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
Huang C; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
Huang Y; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
Yu Y; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
Wu G; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
Guo F; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
Jiang Y; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
Wan S; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
Zhu Z; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
Tian Y; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
Zhu J; Affiliated Foshan Maternity & Child Healthcare Hospital, Southern Medicinal University (Foshan Maternity & Child Healthcare Hospital), Foshan, China.
Zhang J; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
Pokaż więcej
Źródło:
Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2023 Dec; Vol. 38 (1), pp. 2227779.
Typ publikacji:
Journal Article
MeSH Terms:
Protein-Tyrosine Kinases*
Lung Neoplasms*
Humans ; Anaplastic Lymphoma Kinase ; Drug Resistance, Neoplasm ; Proto-Oncogene Proteins/genetics ; Proto-Oncogene Proteins/chemistry ; Crizotinib/pharmacology ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/chemistry ; Mutation ; Cell Line, Tumor
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Crizotinib combined with bronchoscopic interventional treatment in ALK-positive inflammatory myofibroblastic tumor of left main stem bronchus: a case report.
Autorzy:
Zhang P; Department of Cardiothoracic Surgery, The 961st Hospital of Joint Logistics Support Force of PLA, Qiqihar, 230200, China.
Wang C; Department of Emergency and Critical Care Medicine, The 961st Hospital of Joint Logistics Support Force of PLA, Qiqihar, 230200, China.
Lv Z; Department of Pathology, Changzheng Hospital, Naval Medical University, Shanghai, 200040, China.
Du M; Department of Cardiothoracic Surgery, The 961st Hospital of Joint Logistics Support Force of PLA, Qiqihar, 230200, China.
Xu R; Department of Cardiothoracic Surgery, The 960th Hospital of Joint Logistics Support Force of PLA, No. 25 Shifan Road, Tianqiao District, Jinan, 250031, People's Republic of China. .
Pokaż więcej
Źródło:
Journal of cardiothoracic surgery [J Cardiothorac Surg] 2023 Nov 10; Vol. 18 (1), pp. 318. Date of Electronic Publication: 2023 Nov 10.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Granuloma, Plasma Cell*/diagnosis
Granuloma, Plasma Cell*/drug therapy
Granuloma, Plasma Cell*/surgery
Male ; Humans ; Adolescent ; Crizotinib/therapeutic use ; Anaplastic Lymphoma Kinase/genetics ; Protein Kinase Inhibitors/therapeutic use ; Bronchi
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
AGE/RAGE axis regulates reversible transition to quiescent states of ALK-rearranged NSCLC and pancreatic cancer cells in monolayer cultures.
Autorzy:
Kadonosono T; School of Life Science and Technology, Tokyo Institute of Technology, Yokohama, 226-8501, Japan.
Miyamoto K; School of Life Science and Technology, Tokyo Institute of Technology, Yokohama, 226-8501, Japan.
Sakai S; School of Life Science and Technology, Tokyo Institute of Technology, Yokohama, 226-8501, Japan.
Matsuo Y; Department of Human Stress Response Science, Institute of Biomedical Science, Kansai Medical University, Hirakata, 573-1010, Japan.
Kitajima S; Institute for Advanced Biosciences, Keio University, Tsuruoka, 997-0052, Japan.
Wang Q; School of Life Science and Technology, Tokyo Institute of Technology, Yokohama, 226-8501, Japan.
Endo M; School of Life Science and Technology, Tokyo Institute of Technology, Yokohama, 226-8501, Japan.
Niibori M; School of Life Science and Technology, Tokyo Institute of Technology, Yokohama, 226-8501, Japan.
Kuchimaru T; Center for Molecular Medicine, Jichi Medical University, Shimotsuke, 329-0498, Japan.
Soga T; Institute for Advanced Biosciences, Keio University, Tsuruoka, 997-0052, Japan.
Hirota K; Department of Human Stress Response Science, Institute of Biomedical Science, Kansai Medical University, Hirakata, 573-1010, Japan.
Kizaka-Kondoh S; School of Life Science and Technology, Tokyo Institute of Technology, Yokohama, 226-8501, Japan. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2022 Jun 14; Vol. 12 (1), pp. 9886. Date of Electronic Publication: 2022 Jun 14.
Typ publikacji:
Journal Article
MeSH Terms:
Anaplastic Lymphoma Kinase*/genetics
Anaplastic Lymphoma Kinase*/metabolism
Antigens, Neoplasm*/metabolism
Carcinoma, Non-Small-Cell Lung*
Lung Neoplasms*/genetics
Lung Neoplasms*/metabolism
Lung Neoplasms*/pathology
Mitogen-Activated Protein Kinases*/metabolism
Pancreatic Neoplasms*/genetics
Pancreatic Neoplasms*/metabolism
Pancreatic Neoplasms*/pathology
Receptor for Advanced Glycation End Products*/metabolism
A549 Cells ; Cell Hypoxia ; Cell Proliferation/genetics ; Cell Proliferation/physiology ; Humans ; Neoplasm Recurrence, Local/genetics ; Neoplasm Recurrence, Local/metabolism ; Neoplasm Recurrence, Local/pathology ; Receptor Protein-Tyrosine Kinases/metabolism ; Signal Transduction ; Pancreatic Neoplasms
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Multifaceted Roles of ALK Family Receptors and Augmentor Ligands in Health and Disease: A Comprehensive Review.
Autorzy:
Katic L; Department of Medicine, Icahn School of Medicine at Mount Sinai Morningside/West, 1000 Tenth Avenue, New York, NY 10019, USA.; Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA.
Priscan A; Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06520, USA.
Pokaż więcej
Źródło:
Biomolecules [Biomolecules] 2023 Oct 07; Vol. 13 (10). Date of Electronic Publication: 2023 Oct 07.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Receptor Protein-Tyrosine Kinases*/genetics
Receptor Protein-Tyrosine Kinases*/metabolism
Neoplasms*/drug therapy
Neoplasms*/genetics
Humans ; Anaplastic Lymphoma Kinase/genetics ; Anaplastic Lymphoma Kinase/metabolism ; Signal Transduction ; Pain ; Ligands
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 7570

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies